Dr. Daneng Li, MD
Claim this profileCity of Hope
Expert in Cancer
Expert in Hepatocellular Carcinoma
27 reported clinical trials
42 drugs studied
About Daneng Li, MD
Education:
- Earned an undergraduate degree from The Ohio State University, graduating summa cum laude.
- Obtained a Medical degree (MD) from an unspecified institution.
Experience:
- Practices medicine at City of Hope, although specific details are not provided.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HLA-A positive
2Hepatocellular Carcinoma
Global LeaderStage IV
Stage III
HLA-A positive
Affiliated Hospitals
Clinical Trials Daneng Li, MD is currently running
Triapine + Targeted Radiation
for Neuroendocrine Cancer
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Recruiting1 award Phase 2
Voyager V1 + Cemiplimab
for Melanoma
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Recruiting1 award Phase 2
More about Daneng Li, MD
Clinical Trial Related4 years of experience running clinical trials · Led 27 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Daneng Li, MD has experience with
- Lutetium Lu 177 Dotatate
- Nivolumab
- Ipilimumab
- Sorafenib
- Atezolizumab
- SRF388
Breakdown of trials Daneng Li, MD has run
Cancer
Hepatocellular Carcinoma
Liver Cancer
Neuroendocrine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daneng Li, MD specialize in?
Daneng Li, MD focuses on Cancer and Hepatocellular Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Daneng Li, MD currently recruiting for clinical trials?
Yes, Daneng Li, MD is currently recruiting for 10 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Daneng Li, MD has studied deeply?
Yes, Daneng Li, MD has studied treatments such as Lutetium Lu 177 Dotatate, Nivolumab, Ipilimumab.
What is the best way to schedule an appointment with Daneng Li, MD?
Apply for one of the trials that Daneng Li, MD is conducting.
What is the office address of Daneng Li, MD?
The office of Daneng Li, MD is located at: City of Hope, Duarte, California 91012 United States. This is the address for their practice at the City of Hope.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.